Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 312
Selected: 0
NCT IDTitle
NCT01163149Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
NCT01419028A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
NCT04725812Complement Regulation to Undo Systemic Harm in Preeclampsia
NCT02003144An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
NCT04560816A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
NCT01358370A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype
NCT05981092A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)
NCT05780645A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants
NCT01454986Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects
NCT00546260Safety and Efficacy Study of Adjunctive Antiplatelet Therapy Prior to Primary PCI in Patients With STEMI
NCT01194973An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
NCT05288673A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants
NCT04369469Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia
NCT02128269Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
NCT07081646A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT05751642Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
NCT04802083COVID-19 Soliris Expanded Access Protocol
NCT04557735Study of Ravulizumab in Pediatric Participants With HSCT-TMA
NCT04935294Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction
NCT05876351Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
NCT01371825Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
NCT01374360Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry
NCT03551730Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)
NCT00844428Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS
NCT04564339Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
NCT04320602Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
NCT00751231A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
NCT01892345A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
NCT01522183Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01765855An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects
NCT06398158Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
NCT05319912A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
NCT01770951A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT03384186A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants
NCT05501717Safety, PK/PD, and Immunogenicity Study of SC ALXN2030 in Healthy Participants
NCT06291376Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT00122304Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab
NCT04422431Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840
NCT04940559Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants
NCT04355494SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19
NCT02598583Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04920370Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects
NCT01522170aHUS Observational Long Term Follow-Up
NCT03346083Study Evaluating Betrixaban in Pediatric Participants
NCT04609670Study of Radiolabeled ALXN2050 in Healthy Adult Males
NCT00380159Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
NCT05346354Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
NCT01176266Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)
NCT04709094A Drug Interaction Study of Danicopan
NCT07413250Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data